Clinical Trials Logo

Preleukemia clinical trials

View clinical trials related to Preleukemia.

Filter by:

NCT ID: NCT00744757 Completed - Clinical trials for Myelodysplastic Syndrome

An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)

Start date: August 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the response rate of decitabine in previously treated and untreated Taiwanese participants with Myelodysplastic Syndrome (MDS - a disease associated with decreased production of blood cells, blood cells are produced but do not mature normally).

NCT ID: NCT00744536 Completed - Clinical trials for Myelodysplastic Syndromes

Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS

REMMYDYS
Start date: January 2008
Phase: Phase 2
Study type: Interventional

Angiogenesis increases in higher risk MDS patients and those with proliferative CMML. Angiogenesis is associated with increased risk of leukemic transformation and poorer prognoses. Low dose chemotherapy may have anti-angiogenic properties by targetting the genetically stable endothelial cells. Lenalidomide has been recently shown to be highly effective as monotherapy in low/low-intermediate risk MDS, particularly in the subgroup harboring a 5q- deletion. Lenalidomide has not been well studied in higher risk MDS although there are some reports of lenalidomide's efficacy in RAEB-T and AML. One potential mode of action of lenalidomide is inhibition of angiogenesis. The investigators hypothesize that by combining lenalidomide with low dose melphalan in higher risk MDS the investigators will more effectively block angiogenesis and achieve responses or hematologic improvement in MDS.

NCT ID: NCT00741234 Completed - Solid Tumors Clinical Trials

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

Start date: April 2007
Phase: Phase 1
Study type: Interventional

This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with advanced solid tumors. Arm B will assess the safety and tolerability of escalating doses in cohorts of patients with advanced hematologic malignancies. Arm C will assess the safety and tolerability of SB939 in combination with standard azacitidine therapy.

NCT ID: NCT00737516 Completed - Lymphoma Clinical Trials

Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation

Start date: January 2000
Phase: Phase 2
Study type: Interventional

The National Marrow Donor Program (NMDP) has established a system for registering, matching, and tracking unrelated donor cord blood units (CBUs) and transplant outcomes. Study subjects are donors who enroll through collaborating cord blood banks. This study creates uniform collection, screening, testing and storage requirements for cord blood units. The purpose of standardization is to improve efficiency in the selection of cord blood units for transplantation.

NCT ID: NCT00732316 Completed - Leukemia Clinical Trials

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome

Start date: April 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Giving low doses of chemotherapy and antithymocyte globulin before a donor stem cell transplant helps stop the growth of cancer and abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer and abnormal cells (graft-versus-tumor effect). PURPOSE: This phase II trial is studying how well a donor stem cell transplant works after busulfan, fludarabine, and antithymocyte globulin in treating patients with hematologic cancer or myelodysplastic syndrome.

NCT ID: NCT00731328 Completed - Leukemia Clinical Trials

Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome

Start date: April 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Giving low doses of chemotherapy and antithymocyte globulin before a donor stem cell transplant helps stop the growth of abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining abnormal cells (graft-versus-tumor effect). PURPOSE: This phase II trial is studying how well a donor stem cell transplant works after busulfan, fludarabine, methylprednisolone, and antithymocyte globulin in treating patients with bone marrow failure syndrome.

NCT ID: NCT00723112 Completed - Clinical trials for Myelodysplastic Syndrome

The Role of Erythropoietin in Myelodysplastic Syndrome

Start date: February 2007
Phase: N/A
Study type: Observational

The purpose of the study is to elucidate the causative molecular events responsible for the abnormal erythropoiesis in MDS.

NCT ID: NCT00721214 Completed - Clinical trials for Myelodysplastic Syndrome

5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

Start date: July 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine the feasibility and efficacy of using the demethylating agent 5-Azacytidine prior to allogeneic stem cell transplantation in patients with high risk myelodysplastic syndrome (MDS).

NCT ID: NCT00719836 Completed - Clinical trials for Myelodysplastic Syndromes

A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies

Start date: August 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This study consists of two phases: the first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once daily in subjects with advanced myeloid malignancies; the second portion of the study is a Phase 2 study to define the efficacy and safety profile of single-agent SB1518 at the recommended dose in subjects with chronic idiopathic myelofibrosis (CIMF).

NCT ID: NCT00719563 Completed - Lymphoma Clinical Trials

American Ginseng in Treating Patients With Fatigue Caused by Cancer

Start date: October 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue. PURPOSE: This randomized phase III trial is studying American ginseng to see how well it works in treating patients with fatigue caused by cancer.